AbbVie shares have retreated by 3% over the past month following public denials of takeover interest by multiple suitors. Despite this short-term pullback, the company’s core immunology franchises—particularly Skyrizi and Rinvoq—continue to generate robust growth, with combined global sales rising by 18% year-over-year in the latest quarterly report. Management cites a deep late-stage pipeline, including six assets in Phase III trials across immunology and neuroscience, as a key driver of long-term shareholder value. Institutional investors point to the stock’s forward dividend yield of approximately 4.5% and a share buyback authorization of $5 billion over the next 12 months as further support for a constructive outlook.

On Monday, AbbVie announced a strategic partnership with RemeGen to co-develop an experimental antibody-drug conjugate targeting multiple solid tumor indications. Under the agreement, AbbVie will pay up to $300 million upfront and is eligible for up to $4.65 billion in regulatory and commercial milestones. The collaboration leverages RemeGen’s proprietary linker technology and AbbVie’s clinical development infrastructure, with a Phase I study expected to begin in the second quarter. Analysts estimate peak sales potential of $2.5 billion annually if the asset secures approvals in breast and gastric cancer settings.

AbbVie has reached a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, from West Pharmaceutical Services. The transaction, valued at approximately $175 million for the asset and associated intellectual property, is slated to close in mid-2026. AbbVie plans to invest an additional $175 million to modernize the site and integrate it into its global network, creating roughly 200 new positions. This acquisition forms part of a broader commitment to invest over $10 billion in U.S. manufacturing capacity over the next decade, aimed at supporting production of current immunology and next-generation neuroscience therapies.